🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

14,283 results for “B” Clear

  1. OPDIVO 10 mg/mL concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, BI 1810631, Tecentriq 1 200 mg concentrate for solution for infusion

    Boehringer Ingelheim

    Non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  2. OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab, Sodium chloride 0.9%, solution for infusion, 5% Dextrose, solution for infusion

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Renal Cell Carcinoma with Intermediate- or Poor-Risk Factors

    phase 3 small molecule active

    1 trial

  3. OPDIVO 10 mg/mL concentrate for solution for infusion., LENVATINIB, YERVOY 5 mg/ml concentrate for solution for infusion, Sorafenib 200mg Film-Coated Tablets

    Bristol-Myers Squibb Australia Pty Ltd

    Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Carcinoma

    phase 3 small molecule active

    1 trial

  4. OPDIVO 10 mg/mL concentrate for solution for infusion., Nivolumab/Relatlimab

    Bristol-Myers Squibb Australia Pty Ltd

    Previously Untreated Metastatic or Unresectable Melanoma

    phase 3 small molecule active

    1 trial

  5. OPDIVO 10 mg/mL concentrate for solution for infusion., OPDIVO 10 mg/mL concentrate for solution for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, YERVOY 5 mg/ml concentrate for solution for infusion, LENVIMA 10 mg hard capsules, AXITINIB SANDOZ 5 mg, comprimé pelliculé, CABOMETYX 40 mg film-coated tablets

    The George Institute

    Metastatic renal cell carcinoma (mRCC)

    phase 3 small molecule active

    1 trial

  6. OPDIVO 10 mg/mL concentrate for solution for infusion., OPDIVO 10 mg/mL concentrate for solution for infusion., US Opdivo

    Mabxience Research SL

    Previously Untreated Advanced (Unresectable or Metastatic) Melanoma

    phase 3 small molecule active

    1 trial

  7. OPDIVO 10 mg/mL concentrate for solution for infusion., TIVOZANIB, TIVOZANIB

    Lacuna Pharma Pty Ltd

    Renal cell carcinoma

    phase 3 small molecule active

    1 trial

  8. ORAVESCENT Fentanyl Citrate

    Teva Pharma GmbH

    Chronic Low Back Pain

    phase 3 small molecule completed

    1 trial

  9. ORAVESCENT Fentanyl Citrate

    Teva Pharma GmbH

    Chronic Neuropathic Pain

    phase 3 small molecule completed

    1 trial

  10. ORENCIA 250 mg powder for concentrate for solution for infusion, METHOTREXATE/PFIZER, ORENCIA 250 mg powder for concentrate for solution for infusion, ORENCIA 250 mg powder for concentrate for solution for infusion, DRL_AB

    Dr Reddy''s Laboratories (Australia) Pty Ltd

    Rheumatoid Arthritis

    phase 3 small molecule active

    1 trial

  11. ORFORGLIPRON, ORFORGLIPRON, ORFORGLIPRON, ORFORGLIPRON, Orforglipron, Placebo to match LY, ORFORGLIPRON

    Eli Lilly Co.

    Hypertension

    phase 3 small molecule active

    1 trial

  12. ORMD-0801

    ORAMED PHARMACEUTICALS INC.

    T2DM (Type 2 Diabetes Mellitus)

    phase 3 small molecule terminated

    1 trial

  13. ORMD-0801

    ORAMED PHARMACEUTICALS INC.

    Diabetes Mellitus, Type 2

    phase 3 small molecule active

    2 trials

  14. ORMD-0801 (qd)

    ORAMED PHARMACEUTICALS INC.

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  15. ORMD-0801 8 mg

    ORAMED PHARMACEUTICALS INC.

    Type 2 Diabetes Mellitus

    phase 3 small molecule active

    1 trial

  16. OXALIPLATIN , Placebo to MK-3475, CAPECITABINE , CALCIUM FOLINATE , FLUOROURACIL , CISPLATIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOCETAXEL

    Merck Sharp and Dohme

    Gastric and gastroesophageal junction (GEJ) adenocarcinoma

    phase 3 small molecule active

    1 trial

  17. OXALIPLATIN, Bemarituzumab, Placebo for AMG 552, FLUOROURACIL, FOLINIC ACID

    Amgen

    Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer with FGFR2b overexpression

    phase 3 small molecule active

    1 trial

  18. OXALIPLATIN, CALCIUM FOLINATE, FLUOROURACIL, BNT327 20 mg ml, CAPECITABINE, BEVACIZUMAB, IRINOTECAN HYDROCHLORIDE TRIHYDRATE, BNT327 50 mg ml, CAPECITABINE

    Bristol-Myers Squibb Australia Pty Ltd

    Untreated, Unresectable or Metastatic Colorectal Cancer

    phase 3 small molecule active

    1 trial

  19. OXALIPLATIN, CALCIUM LEVOFOLINATE, FOLINIC ACID, FLUOROURACIL

    Ningbo Cancer Hospital

    Patients ≥75 years old with cT3/T4 rectal adenocarcinoma eligible to radiotherapy, FOLFOX chemotherapy and total mesorectal excision (TME) surgery

    phase 3 small molecule active

    1 trial

  20. OXALIPLATIN, FOLINIC ACID, IRINOTECAN, FLUOROURACIL

    Ningbo Cancer Hospital

    High-risk stage III colon cancer

    phase 3 small molecule active

    1 trial

  21. Obatoclax Mesylate, Carboplatine and Etoposide

    Teva Pharma GmbH

    Extensive-stage Small Cell Lung Cancer

    phase 3 small molecule terminated

    1 trial

  22. Obexelimab

    Zenas BioPharma

    IgG4 Related Disease

    phase 3 small molecule active

    1 trial

  23. Obexelimab

    Zenas BioPharma

    Warm Autoimmune Hemolytic Anemia

    phase 3 small molecule active

    1 trial

  24. Obinutuzumab

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 3 mab terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources